Every 8-K that Werewolf Therapeutics, Inc. (HOWL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow HOWL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HOWL filings page.
Werewolf Therapeutics, Inc. (HOWL) entered into a definitive all‑stock merger agreement to combine with Ambros Therapeutics, with Ambros becoming a wholly owned subsidiary and the combined company expected to operate as Ambros Therapeutics and trade on Nasdaq as “AMBX.” Ambros stockholders will receive Werewolf common stock or pre‑funded warrants based on an exchange ratio reflecting an implied $500.0 million valuation for Ambros and $47.5 million for Werewolf.
On a fully diluted, treasury‑stock basis, pre‑merger Werewolf holders (excluding PIPE participants) are expected to own 6.8% of the combined company, pre‑merger Ambros stockholders 71.7%, and PIPE investors 21.5%, subject to adjustments including Werewolf net cash. Concurrently, Werewolf agreed to a $150.0 million private placement of common stock and PIPE pre‑funded warrants, with proceeds expected to fund Ambros’s pivotal CRPS‑RISE Phase 3 trial of neridronate and a planned NDA submission, providing cash runway into the first half of 2029. Existing Werewolf holders will receive one non‑transferable contingent value right per share tied to potential monetization of Werewolf’s legacy INDUKINE assets.
Werewolf Therapeutics, Inc. (HOWL) entered into an asset purchase agreement with EMD Serono Research & Development Institute Inc. on August 14, 2026, selling pre-clinical technology comprising its INDUCER platform and its INDUKINE platform (excluding the WTX-124 and WTX-330 clinical development programs) as the Transferred Assets. Werewolf retains all rights needed to continue developing its WTX-124 and WTX-330 clinical programs.
As consideration, EMD agreed to pay Werewolf upfront cash of $28.0 million plus an additional $5.0 million upon completion of the technology transfer. The parties provided customary representations, warranties, indemnities and a non-competition covenant under which Werewolf will not exploit certain compounds directed to the same tumor targets as any Transferred Compound for 24 months after closing, subject to change-of-control exceptions. Concurrently, EMD granted Werewolf an exclusive license to certain Transferred Assets patents necessary to conduct clinical development for WTX-124 and WTX-330, and additional license rights to support Werewolf’s existing collaboration arrangements with Harpoon Therapeutics, Inc. and Jazz Pharmaceuticals Ireland Limited.
Werewolf Therapeutics, Inc. reported second quarter 2026 results highlighted by a shift to profitability and a major asset transaction. The company entered into an asset purchase agreement with Jazz Pharmaceuticals Ireland Limited for its JZP898 program and repaid all amounts owed under its loan and security agreement with K2 HealthVentures LLC. These transactions included a $21.0 million payment to Werewolf and support ongoing evaluation of strategic alternatives with financial advisor Piper Sandler.
For the quarter ended June 30, 2026, collaboration revenue was $21.0 million, research and development expenses were $6.2 million versus $13.1 million a year earlier, and general and administrative expenses were $7.7 million versus $4.4 million. Net income was $3.7 million, compared with a net loss of $18.0 million in the prior-year period. As of June 30, 2026, cash and cash equivalents were $22.0 million, compared with $46.5 million as of March 31, 2026, and management expects existing cash to fund operations into the second quarter of 2027 while advancing INDUKINE and INDUCER pipeline programs, including WTX-124 and WTX-330.
Werewolf Therapeutics reported first quarter 2026 results and outlined major corporate moves alongside an ongoing strategic review led by Piper Sandler. The company entered an asset purchase agreement giving Jazz Pharmaceuticals exclusive global rights to JZP898 and repaid all amounts owed under its loan with K2 HealthVentures.
Cash and cash equivalents were $46.5 million as of March 31, 2026, down from $57.1 million at year-end 2025. First quarter research and development expenses fell to $8.2 million from $13.1 million a year earlier, while general and administrative expenses were $5.1 million, slightly above $4.9 million in 2025. Net loss narrowed to $13.5 million from $18.1 million, or $0.28 per basic and diluted share versus $0.40.
Working capital declined to $10.2 million and stockholders’ equity to $12.2 million as of March 31, 2026, reflecting continued operating losses and leverage, including $28.8 million of notes payable before the subsequent loan repayment.
Werewolf Therapeutics reported fourth quarter and full-year 2025 results and launched a formal review of strategic alternatives that could include a sale, merger, asset sale, licensing deals or other transactions. The company hired Piper Sandler as exclusive financial advisor and emphasized there is no set timeline or assurance any deal will occur.
For the quarter ended December 31, 2025, net loss narrowed to $8.4M from $20.4M a year earlier, driven by lower research and development expenses of $6.9M versus $15.7M, and general and administrative expenses of $2.5M versus $4.6M. Full-year 2025 net loss improved to $60.8M from $70.5M, with R&D at $44.8M and G&A at $15.8M.
As of December 31, 2025, cash and cash equivalents were $57.1M, down from $111.0M a year earlier. The company expects this cash to fund operations into the fourth quarter of 2026, while it continues advancing its INDUKINE and INDUCER immune-oncology platforms and clinical candidates WTX-124 and WTX-330.
Werewolf Therapeutics, Inc. announced that its board has initiated a process to explore a full range of strategic alternatives to advance its drug development platform and pipeline and to maximize stockholder value. The company has engaged Piper Sandler & Co. as its exclusive financial advisor for this evaluation.
Potential options under consideration include a sale of the company, a business combination or merger, a sale of assets, licensing or collaboration arrangements, or other strategic transactions. Werewolf stated it has no defined timeline for this review and there is no assurance that the process will result in any transaction or agreement, and it does not intend to provide further updates unless a specific action is approved or additional disclosure is deemed appropriate.
Werewolf Therapeutics, Inc. approved a major restructuring that will cut 64% of its workforce, with the reduction expected to be largely complete by February 13, 2026. The company plans to record an estimated $4.1 million one-time charge in the first quarter of 2026 for severance and related cash benefits.
As part of this action, Chief Financial Officer Timothy W. Trost and Chief Medical Officer Dr. Randi Isaacs will resign their roles effective February 13, 2026, each receiving severance equal to nine months of base salary plus nine months of company-paid COBRA contributions and extended stock option exercise periods. Both will continue under consulting agreements at $250 per hour for up to six months. The company appointed Michael Urban, previously Vice President of Finance and Corporate Controller, as principal financial and accounting officer effective February 13, 2026.
The company also disclosed that in late 2025 and early 2026 it sought to raise capital and is now evaluating alternatives to maximize stockholder value, including strategic partnerships for its WTX-124 and WTX-330 INDUKINE programs, with no assurance any transaction will occur.
Werewolf Therapeutics, Inc. received a Nasdaq notice on February 4, 2026, stating its common stock has closed below $1.00 per share for 30 consecutive business days, failing the Nasdaq Global Select Market minimum bid price requirement.
The company has an initial 180‑day grace period, until August 3, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for 10 consecutive business days. If it does not regain compliance, it may seek an additional 180‑day period by transferring to the Nasdaq Capital Market, or its stock could ultimately face delisting, subject to appeal rights.
Werewolf Therapeutics reported new data from its INDUKINE™ pipeline and outlined priorities for 2026. For WTX-124, Phase 1/1b data as of October 2025 showed objective, durable responses as a monotherapy in several solid tumors and in combination with pembrolizumab. In heavily pretreated advanced cutaneous melanoma, monotherapy delivered a 21% objective response rate, rising to 30% in patients who had previously responded to immunotherapy, with no vascular leak syndrome and limited high-grade side effects. The FDA accepted 18 mg as the recommended dose and provided initial guidance for a monotherapy registration path in relapsed or refractory melanoma after immune checkpoint inhibitors.
For WTX-330, Phase 1b/2 data in the first twelve patients showed favorable tolerability and antitumor activity using an optimized manufacturing process that improved safety, pharmacokinetics, and therapeutic index. At 0.024 mg/kg IV twice weekly, WTX-330 reached a 17-fold higher Cmax than published rhIL-12 with only 0.12% free IL-12, and there was a confirmed partial response in metastatic gall bladder cancer with a 45% tumor reduction. Werewolf plans additional WTX-124 and WTX-330 data in the first half of 2026, is seeking strategic partnerships, and notes that further development and planned INDs for INDUCER T-cell engager candidates WTX-1011 and WTX-2022 will require additional funding.
Werewolf Therapeutics furnished a press release announcing financial results for the quarter ended September 30, 2025.
The company reported this under Item 2.02 of an 8-K on November 4, 2025, and stated the information, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act.
The filing also includes a caution regarding forward-looking statements.
Werewolf Therapeutics, Inc. reported a material event notifying that it is presently non-compliant with Nasdaq listing rule 5605(c)(2) because of the passing of director Dr. Lazarus. The company cites Nasdaq Listing Rule 5605(c)(4)(B), which provides a cure period to restore compliance. That cure period will end on the earlier of the company’s next annual meeting of stockholders or September 30, 2026. The filing is signed by Timothy W. Trost, Chief Financial Officer and Treasurer.
Werewolf Therapeutics announced that it furnished a press release reporting its financial results for the quarter ended June 30, 2025, and that the press release is provided as Exhibit 99.1. The company also made an updated corporate investor presentation publicly available and furnished it as Exhibit 99.2. The filing specifies that these items are being furnished rather than filed under the Exchange Act and includes a standard cautionary note describing forward-looking statements and associated development, regulatory, and financing risks.
The 8-K does not include the financial figures within its text but notifies investors where the results and presentation are available as exhibits for review.